Bone Biologics Corp
BBLG- Exchange
- Nasdaq
- Industry
- Orthopedic, Prosthetic & Surgical Appliances & Supplies
- SEC CIK
- 0001419554
No open-market purchases or sales by Bone Biologics Corp insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q3 2026, worth $215.1K in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 27, 2026, 1:07 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | – | – |
| Operating expenses | $3.23M | $4.22M | $9.43M | $3.67M | $1.10M |
| Research and development | $1.06M | $2.13M | $6.91M | $1.58M | $82.0K |
| Selling, general and administrative | $2.17M | $2.09M | $2.52M | $2.09M | $1.02M |
| Operating income | -$3.23M | -$4.22M | -$9.43M | -$3.67M | -$1.10M |
| Income tax | – | – | – | – | $1.60K |
| Net income | -$3.11M | -$4.11M | -$8.95M | -$1.48M | -$1.61M |
| EPS, basic | $-2.65 | $-4.83 | $-34.01 | $-0.13 | – |
| EPS, diluted | $-2.65 | $-4.83 | $-34.01 | – | – |
| Weighted shares, basic | 1.17M | 1.52M | 263.1K | – | – |
| Weighted shares, diluted | 1.17M | 1.52M | 263.1K | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | – | – |
| Cash and equivalents | $5.33M | $3.33M | $3.03M | $7.54M | $6.68M |
| Total current assets | $5.80M | $3.86M | $3.74M | – | – |
| Total assets | $5.80M | $3.86M | $3.74M | $8.50M | $6.68M |
| Total current liabilities | $418.6K | $377.7K | $831.4K | $2.55M | – |
| Total liabilities | $418.6K | $377.7K | $831.4K | $2.55M | $99.9K |
| Shareholders' equity | $5.38M | $3.48M | $2.91M | $5.95M | $6.58M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | – | – |
| Operating cash flow | -$2.69M | -$4.12M | -$9.56M | -$3.57M | -$1.23M |
| Stock-based compensation | $256.4K | $188.8K | $152.6K | $266.6K | $207.0K |
| Financing cash flow | $4.70M | $4.42M | $5.04M | $4.43M | $7.90M |
| Net change in cash | $2.01M | $298.6K | -$4.51M | $862.9K | $6.68M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 26, 2026 | 3.39M | +88.8% | SEC |
| Aug 14, 2026 | 2.76M | +53.5% | SEC |
| May 14, 2026 | 1.80M | −45.1% | SEC |
| Feb 23, 2026 | 1.80M | −45.1% | SEC |
| Nov 14, 2025 | 1.80M | −27.1% | SEC |
| Aug 14, 2025 | 1.80M | −0.3% | SEC |
| May 1, 2025 | 3.27M | +197.2% | SEC |
| Feb 19, 2025 | 3.27M | +512.3% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.